Table 1 Basic information of included studies
References | Country | Study design | Study interval | Sample size (LG/OG) | Neoadjuvant regimen | Follow-up, months |
|---|---|---|---|---|---|---|
Cui et al. 2022 [28] | China | R; S | 2012–2019 | 136 (61/75) | SOX; XELOX; SF; DCF | 69 (range, 1–112) |
Fujisaki et al. 2020 [29] | Japan | R; S | 2009–2018 | 49 (20/29) | SP; SOX; Trastuzumab + SOX; Trastuzumab + CAPOX | 38 (range, 3–115) |
Ge et al. 2022 [30] | China | R; S | 2017–2019 | 153 (77/76) | XELOX; FOLFOX; SOX; FLOT | NA |
Hu et al. 2022 [31] | China | R; S; PSM | 2011–2018 | 138 (69/69) | SOX; XELOX; CS; FOLFOX; TP; ECF; DCF; DCX; Chemoradiotherapy with S-1 | 45 (range, 3–94) |
Hu et al. 2022 [32] | China | R; S; PSM | 2018–2020 | 66 (34/32) | SOX; FLOT | NA |
Khaled et al. 2021 [34] | Egypt | R; M | NA | 84 (41/43) | XELOX | NA |
Li et al. 2016 [35] | China | P; S | 2012–2014 | 44 (20/24) | SOX; CAPOX; FOLFOX7 | NA |
Li et al. 2019 [26] | China | RCT; S | 2015–2017 | 95 (45/50) | XELOX | NA |
Shen et al. 2020 [33] | China | R; S | 2018–2020 | 90 (45/45) | XELOX | NA |
van der Wielen et al. 2020 [27] | Europe | RCT; M | 2015–2018 | 96 (47/49) | ECC; ECF; EOX; FOLFOX; FLOT | NA |
Wang et al. 2014 [36] | China | R; S | 2011–2014 | 120 (68/52) | XELOX | NA |
Wang,2016 [37] | China | R; S | 2013–2014 | 134 (67/67) | XELOX | NA |
Wang et al. 2020 [38] | China | R; S | 2007–2016 | 270 (49/221) | XELOX; FOLFOX; SOX; SP; TXT + XELOX; TCF; DOS; TXT + SP; Fluoropyrimidine-based chemoradiotherapy | NA |
Wang et al. 2021 [39] | China | R; S; PSM | 2013–2018 | 69 (23/46) | DC; DS; DX; EP; FOLFIRI; POS; S1; SEEOX; SOX; CAPOX | NA |
Wu et al. 2022 [40] | China | R; S | 2017–2020 | 154 (52/102) | SOX; XELOX; DCF; XP | 31 (range, 2–60) |
Xi et al. 2020 [41] | China | R; S; PSM | 2013–2016 | 90 (45/45) | SOX; XELOX | OG:39 (range, 12–49) LG: 33 (range, 9–58) |
Zheng et al. 2023[42] | China | R; S | 2008–2018 | 146 (89/57) | SOX; XELOX; DS; FOLFOX4; Oxaliplatin + Apatinib | NA |
Zhong et al. 2023[43] | China | R; S; PSM | 2015–2019 | 162 (81/81) | SOX; FLOT; DOS; DCF | NA |